Simulations Plus, Inc. SLP

RESEARCH TRIANGLE PARK, N.C., September 17, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration’s (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technolog

RESEARCH TRIANGLE PARK, N.C., August 13, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the Company's previously announced acquisition by Altaris, LLC.

RESEARCH TRIANGLE PARK, N.C., July 09, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its third quarter fiscal 2026, ended May 31, 2026.

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global In Silico Clinical Trials Market size & share revenue was valued at approximately USD 1.84 Billion in 2025 and is expected to reach USD 2.18 Billion in 2026 and is expected to reach around USD 8.94 Billion by 2035, at a CAGR of 15.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Certara Inc., Simulatio

RESEARCH TRIANGLE PARK, N.C., June 23, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that helps advance biopharma innovation, today announced it is building the agentic layer of Composer, its AI-native platform for model-informed drug development, using the NVIDIA BioNeMo Agent Toolkit.

Sylvania Platinum is in focus after a fresh research update nudged its fair value estimate to £1.73 per share, compared with £1.71 previously, and highlighted a separate price target of 175 GBp from a major research house. Analysts link these figures to what they see as a solid tailings retreatment business and strong cash generation, while questioning how much of that story is already reflected in the current share price. In the sections ahead, you will see how to interpret these shifting...

Certara’s updated analyst model now carries a slightly lower fair value price target of US$7.48, compared with the prior US$7.62, reflecting only a modest adjustment. This small move aligns with recent Street commentary, where bullish analysts highlight profitable operations and long term growth drivers, while more cautious voices trim targets as they reassess valuation multiples and execution timelines. As you read on, you will see how these shifting views fit together and how to keep track...

Completion of the transaction is expected in the fourth quarter of 2026.

RESEARCH TRIANGLE PARK, N.C., June 16, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it has entered into a definitive agreement to be acquired by affiliates of Altaris, LLC ("Altaris"), an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry, in an all-cash transaction. At or about the

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Sylvania Platinum’s latest analyst update leaves the existing price targets unchanged, providing a clear marker of where expectations currently sit. As the story around the stock develops, you can track fresh updates and incorporate them into your own view of the company. Keep reading to learn straightforward ways to follow the evolving analyst narrative and understand what each new data point might mean for your portfolio decisions. Stay updated as the Fair Value for Sylvania Platinum shifts...

While Simulations Plus, Inc. ( NASDAQ:SLP ) might not have the largest market cap around , it saw a significant share...

NVIDIA Corporation (NASDAQ:NVDA) is one of the 10 Best Quality Stocks to Buy and Hold for the Next 5 Years. On May 6, 2026, Simulations Plus announced a technical collaboration with NVIDIA Corporation (NASDAQ:NVDA) focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications used throughout the drug development lifecycle. The collaboration […]